Lab Testing Insights
How Emerging Biomarkers in Non-Small Cell Lung Cancer are Driving New and More Innovative Targeted Treatments
Lung cancer is one of the most common tumors and about 228,000 new cases will be diagnosed in the United...
How Prognos is Using COVID-19 Data
On May 20th, 2020, Jaclyn Fink presented to Women In Data's NYC Chapter on how clinical lab data is being analyzed.
Factor This: The Art and Science of Harmonizing Lab-based Clinical Insights to Make them Analytics Ready
The third blog in our 'Factor This' series featuring Q&A with Prognos subject matter experts.
Factor This: Harnessing Lab-Testing Insights to Support Targeted Oncology Therapies in the Market
The second blog in our 'Factor This' series featuring Q&A with Prognos subject matter experts.
Lab Results Uncover Insights for Marketers
Read an interesting article by Jason Bhan, M.D., Chief Medical Officer of Prognos, here on on PM360.
What to Consider if Your Drug is a Targeted Therapy for a New Biomarker
A Follow Up to “Biomarker Testing in Non-Small Cell Lung Cancer“ By Melissa Leonhauser, General Manager, Alert & Targeting Portfolio...
Available Omnichannel HCP Data Sources
Clinical Diagnostic Data for Omnichannel HCP Promotion Marketing: Part Two We’re excited to share part two of our blog series...
Biomarker Testing in Non-Small Cell Lung Cancer
By Bill Bowman, Clinical Solutions Architect The trend toward precision medicine in oncology is epitomized by the management of patients...
Clinical Diagnostic Data for Omnichannel HCP Marketing
A 5 Part Series By Matt Apprendi, VP of Digital Products We’re excited to write about one of the most...
The Value of Using Lab Data
By Heather Von Allmen Arthur Conan Doyle’s ubiquitous fictional detective Sherlock Holmes once said, “It is a capital mistake to...